Next 10 |
home / stock / srrk / srrk articles
Raymond James has initiated coverage on Scholar Rock Holding (NASDAQ:SRRK), supported by the potential value with a couple of key pr...
U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday. Shares of NIO Inc. (NYSE: NIO) rose during Tuesday&rsquo...
Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with...
Samsara BioCapital GP LLC, 10% Owner at Scholar Rock Holding (NASDAQ:SRRK), reported a large insider buy on October 18, according to a new SEC fili...
Srinivas Akkaraju, Board Member at Scholar Rock Holding (NASDAQ:SRRK), reported a large insider buy on October 18, according to a new SEC filing. ...
Although U.S. stocks closed higher on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence...
Gainers OpGen, Inc. (NASDAQ: OPGN) jumped 593% to $2.33 following two SEC filings from the precision medicine company. The company has received a...
U.S. stocks traded mixed, with the Dow Jones falling around 100 points on Thursday. Here are some big stocks recording gains in today’s sessi...
Gainers Applied UV, Inc. (NASDAQ: AUVI) gained 60.4% to $0.4924. Applied UV said its new product, the Airocide® Pro+ air purification system f...
News, Short Squeeze, Breakout and More Instantly...
Scholar Rock Holding Corporation Company Name:
SRRK Stock Symbol:
NASDAQ Market:
2024-04-24 19:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Raymond James has initiated coverage on Scholar Rock Holding (NASDAQ:SRRK), supported by the potential value with a couple of key pr...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...